Correlation Between Compagnie Generale and Innate Pharma

Can any of the company-specific risk be diversified away by investing in both Compagnie Generale and Innate Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Compagnie Generale and Innate Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Compagnie Generale des and Innate Pharma, you can compare the effects of market volatilities on Compagnie Generale and Innate Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Compagnie Generale with a short position of Innate Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Compagnie Generale and Innate Pharma.

Diversification Opportunities for Compagnie Generale and Innate Pharma

0.91

Correlation Coefficient

Compagnie Generale  Innate Pharma

Almost no diversification

The 3 months correlation between Compagnie and Innate is 0.91. Overlapping area represents the amount of risk that can be diversified away by holding Compagnie Generale des and Innate Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Innate Pharma and Compagnie Generale is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Compagnie Generale des are associated (or correlated) with Innate Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Innate Pharma has no effect on the direction of Compagnie Generale i.e., Compagnie Generale and Innate Pharma go up and down completely randomly.

Pair Corralation between Compagnie Generale and Innate Pharma

Assuming the 90 days horizon Compagnie Generale des is expected to generate 0.59 times more return on investment than Innate Pharma. However, Compagnie Generale des is 1.69 times less risky than Innate Pharma. It trades about -0.14 of its potential returns per unit of risk. Innate Pharma is currently generating about -0.25 per unit of risk. If you would invest  3,545  in Compagnie Generale des on September 2, 2024 and sell it today you would lose (470.00) from holding Compagnie Generale des or give up 13.26% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Strong
Accuracy	100.0%
Values	Daily Returns

Compagnie Generale des  vs.  Innate Pharma

Compagnie Generale des

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Compagnie Generale des has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Innate Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Innate Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's technical indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Compagnie Generale and Innate Pharma

The main advantage of trading using opposite Compagnie Generale and Innate Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Compagnie Generale position performs unexpectedly, Innate Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Innate Pharma will offset losses from the drop in Innate Pharma's long position.

The idea behind Compagnie Generale des and Innate Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.